Metabolomic profiling reveals distinct and shared biology in COPD and IPF.

introductionChronic Obstructive Pulmonary disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) are chronic pulmonary disorders with distinct pathologies but shared risk factors. Metabolomics may provide insights into mechanisms.

objectivesTo identify metabolites associated with COPD and IPF, and to characterize shared and disease-specific signatures.

methodsPlasma metabolomic profiling was conducted in the Lung Tissue Research Consortium (LTRC). Logistic regression identified metabolites associated with COPD and IPF, and results were replicated in an external cohort, COPDGene. We applied Weighted Gene Co-expression Network Analysis (WGCNA) to explore disease-associated metabolite modules. We further evaluated relationships between significant metabolites and risk genes of interest.

resultsOf 1131 metabolites in LTRC, 246 (21.8%) differed between COPD and controls, and 136 (12.0%) between IPF and controls (FDR < 0.05). Among 80 shared significant metabolites in COPD and IPF, 77 showed concordant directions of effect. Shared metabolomic changes included reduced levels of steroids, triglycerides, diglycerides, phosphatidylcholines, and increased levels of carnitines. In contrast, polyunsaturated fatty acids, nicotine, and thyroxine metabolites differed between COPD and IPF; these findings were further explored by the WGCNA. External replication was performed for 120 metabolites measured in both cohorts, of which 49 (40.8%) replicated in COPD vs. control. In exploratory analyses leveraging quantitative imaging abnormalities (QIA) as a surrogate for IPF; only 4 (3.3%) metabolites replicated in the QIA vs. control model, and only 9 (7.5%) for COPD vs. QIA.

conclusionAlterations in metabolomic profiles of COPD and IPF suggested shared dysregulation of several lipids. However, some metabolites pointed to disease-specific differences.